Blueprint Medicines Corporation BPMC reported third-quarter 2024 adjusted loss of 89 cents per share, narrower than the Zacks Consensus Estimate of a loss of 97 cents. The company had incurred a loss ...

Investment analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Blueprint Medicines in a ...

Blueprint Medicines (BPMC) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings ...

Blueprint Medicines (BPMC) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.97. This compares to loss of $2.20 per share a year ago. These figures ...

We feel now is a pretty good time to analyse Blueprint Medicines Corporation's ( NASDAQ:BPMC ) business as it appears... Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma have been ...

Wells Fargo analyst Derek Archila maintained a Buy rating on Blueprint Medicines (BPMC – Research Report) yesterday and set a price target of $151.00. The company’s shares closed yesterday at $89.24.

Below is Validea's guru fundamental report for BLUEPRINT MEDICINES CORP (BPMC). Of the 22 guru strategies we follow, BPMC rates highest using our Quantitative Momentum Investor model based on the ...

Blueprint Medicines Corp. ( (BPMC) ) has realeased its Q3 earnings. Here is a breakdown of the information Blueprint Medicines Corp. presented ...